Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 12/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273093 | 0.85 | TDP1 (0.60) | TDP1TSHRMAPK1VCAM1ALDH1A1 | |
| SCHEMBL6640405 | 0.83 | TDP1 (0.62) | TDP1TSHRMAPK1VCAM1ALDH1A1 | |
| SCHEMBL28187039 | 0.82 | TDP1 (0.47) | TDP1TSHRMAPK1VCAM1ALDH1A1 | |
| SCHEMBL6646572 | 0.81 | TDP1 (0.60) | TDP1TSHRMAPK1VCAM1ALDH1A1 | |
| SCHEMBL6576203 | 0.81 | TDP1 (0.60) | TDP1TSHRMAPK1VCAM1ALDH1A1 | |
| SCHEMBL9512370 | 0.80 | TDP1 (0.48) | TDP1TSHRMAPK1VCAM1ALDH1A1 | |
| SCHEMBL5042301 | 0.79 | TDP1 (0.56) | TDP1TSHRMAPK1VCAM1ALDH1A1 | |
| SCHEMBL31514206 | 0.79 | TDP1 (0.56) | TDP1TSHRMAPK1VCAM1ALDH1A1 | |
| SCHEMBL1626726 | 0.78 | ALDH1A1 (0.44) | TDP1TSHRMAPK1VCAM1ALDH1A1 | |
| SCHEMBL8411786 | 0.78 | GPR35 (0.47) | TDP1TSHRMAPK1VCAM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| US-7279484-B2 | Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease | AJINOMOTO CO., INC. (JP) | 2007-10-09 | — | — | US | disclosed |
| US-7279484-B2 | Suppress tumor necrosis factor; Crohn's disease; imflammatory bowel disorders; sepsis; autoimmune disease | AJINOMOTO CO., INC. (JP) | 2007-10-09 | — | — | US | disclosed |
| EP-1810677-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021069-A1 | Receptor Function Regulating Agent | GPR119, INSR, GPR65 | TDP1 4558/4885TSHR 240/4885MAPK1 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.